Chung-Hung Chen1, Sheng-Lei Yan1, Tsung-Hsun Yang1, Shih-Feng Chen1, Yung-Hsiang Yeh1, Jing-Jim Ou2, Chien-Hua Lin2, Yueh-Tsung Lee2, Chien-Hua Chen3. 1. Division of Gastroenterology, Department of Internal Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan. 2. Division of General Surgery, Department of Surgery, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan. 3. Division of Gastroenterology, Department of Internal Medicine, Chang Hua Show Chwan Memorial Hospital, Changhua, Taiwan.
Abstract
BACKGROUND:Colorectal cancer (CRC) is a common and lethal disease in the world. There is an increasing number of cases in Taiwan and a higher rate at advanced stages. The immune fecal occult blood test (iFOBT) has been used as a screening method in Taiwan for years. A new novel diagnostic tool, the Methylated Septin-9 (MS-9) DNA blood test, had been reported to have high sensitivity and specificity for CRC detection. There are no available data in Taiwan, so we conducted this prospective randomized trial to investigate the relationship among the MS-9 DNA blood test, iFOBT, and a combination of the two tests for diagnosing CRC in Taiwanese people. METHODS:From July 1, 2012 to December 31, 2013, we prospectively selected 60 plasma samples from patients who were diagnosed with CRC and otherwise, the healthy group by colonoscopy in our hospital. Patients were divided into the CRC group and healthy group. CRC stages 0, I, II and stages III and IV were separately analyzed. We calculated the sensitivity and specificity of each group to determine the relationship among the MS-9 DNA blood test, iFOBT, and a combination of the two tests for diagnosing CRC in Taiwanese people. RESULTS: The results of the MS-9 DNA blood test for the 60 samples were divided into three groups, and the sensitivity as well as the specificity of the MS-9 DNA blood test to detect CRC were 47% and 89%, respectively. The results of iFOBT were also divided into three groups, and had higher sensitivity (84%) but lower specificity (55%) using iFOBT to detect CRC. Higher rates could be predicted to detect CRC if both the tests were positive. CONCLUSIONS: A combined MS-9 DNA blood test and iFOBT may help in a higher detection rate of CRC. It could be offered to individuals who are unwilling or unable to undergo colonoscopy. Further large prospective, randomized studies are needed in the future.
RCT Entities:
BACKGROUND:Colorectal cancer (CRC) is a common and lethal disease in the world. There is an increasing number of cases in Taiwan and a higher rate at advanced stages. The immune fecal occult blood test (iFOBT) has been used as a screening method in Taiwan for years. A new novel diagnostic tool, the Methylated Septin-9 (MS-9) DNA blood test, had been reported to have high sensitivity and specificity for CRC detection. There are no available data in Taiwan, so we conducted this prospective randomized trial to investigate the relationship among the MS-9 DNA blood test, iFOBT, and a combination of the two tests for diagnosing CRC in Taiwanese people. METHODS: From July 1, 2012 to December 31, 2013, we prospectively selected 60 plasma samples from patients who were diagnosed with CRC and otherwise, the healthy group by colonoscopy in our hospital. Patients were divided into the CRC group and healthy group. CRC stages 0, I, II and stages III and IV were separately analyzed. We calculated the sensitivity and specificity of each group to determine the relationship among the MS-9 DNA blood test, iFOBT, and a combination of the two tests for diagnosing CRC in Taiwanese people. RESULTS: The results of the MS-9 DNA blood test for the 60 samples were divided into three groups, and the sensitivity as well as the specificity of the MS-9 DNA blood test to detect CRC were 47% and 89%, respectively. The results of iFOBT were also divided into three groups, and had higher sensitivity (84%) but lower specificity (55%) using iFOBT to detect CRC. Higher rates could be predicted to detect CRC if both the tests were positive. CONCLUSIONS: A combined MS-9 DNA blood test and iFOBT may help in a higher detection rate of CRC. It could be offered to individuals who are unwilling or unable to undergo colonoscopy. Further large prospective, randomized studies are needed in the future.
Authors: Theo deVos; Reimo Tetzner; Fabian Model; Gunter Weiss; Matthias Schuster; Jürgen Distler; Kathryn V Steiger; Robert Grützmann; Christian Pilarsky; Jens K Habermann; Phillip R Fleshner; Benton M Oubre; Robert Day; Andrew Z Sledziewski; Catherine Lofton-Day Journal: Clin Chem Date: 2009-04-30 Impact factor: 8.327
Authors: K Birkenkamp-Demtroder; S H Olesen; F B Sørensen; S Laurberg; P Laiho; L A Aaltonen; T F Orntoft Journal: Gut Date: 2005-03 Impact factor: 23.059
Authors: Holli A Loomans-Kropp; Yurong Song; Manish Gala; Aparna R Parikh; Emily E Van Seventer; Rocio Alvarez; Megan P Hitchins; Robert H Shoemaker; Asad Umar Journal: Cancer Res Commun Date: 2022-02-11
Authors: Tobias Niedermaier; Korbinian Weigl; Michael Hoffmeister; Hermann Brenner Journal: United European Gastroenterol J Date: 2017-10-09 Impact factor: 4.623
Authors: Joe Ibrahim; Ken Op de Beeck; Erik Fransen; Lieselot Croes; Matthias Beyens; Arvid Suls; Wim Vanden Berghe; Marc Peeters; Guy Van Camp Journal: Cancer Med Date: 2019-04-16 Impact factor: 4.452
Authors: Sander Bach; Nina R Sluiter; Jamie J Beagan; Joost M Mekke; Johannes C F Ket; Nicole C T van Grieken; Renske D M Steenbergen; Bauke Ylstra; Geert Kazemier; Jurriaan B Tuynman Journal: JNCI Cancer Spectr Date: 2019-06-19